MBX Biosciences (MBX) Competitors $7.79 -0.34 (-4.18%) Closing price 04:00 PM EasternExtended Trading$7.77 -0.02 (-0.26%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock MBX vs. GYRE, SNDX, AUPH, ADPT, SYRE, SPRY, NRIX, ELVN, NTLA, and BGMShould you be buying MBX Biosciences stock or one of its competitors? The main competitors of MBX Biosciences include Gyre Therapeutics (GYRE), Syndax Pharmaceuticals (SNDX), Aurinia Pharmaceuticals (AUPH), Adaptive Biotechnologies (ADPT), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Nurix Therapeutics (NRIX), Enliven Therapeutics (ELVN), Intellia Therapeutics (NTLA), and Qilian International Holding Group (BGM). These companies are all part of the "pharmaceutical products" industry. MBX Biosciences vs. Gyre Therapeutics Syndax Pharmaceuticals Aurinia Pharmaceuticals Adaptive Biotechnologies Spyre Therapeutics ARS Pharmaceuticals Nurix Therapeutics Enliven Therapeutics Intellia Therapeutics Qilian International Holding Group MBX Biosciences (NYSE:MBX) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk. Which has higher valuation and earnings, MBX or GYRE? MBX Biosciences has higher earnings, but lower revenue than Gyre Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMBX BiosciencesN/AN/AN/AN/AN/AGyre Therapeutics$105.76M8.40-$92.93M$0.05189.80 Do institutionals and insiders hold more shares of MBX or GYRE? 24.0% of Gyre Therapeutics shares are held by institutional investors. 19.5% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community favor MBX or GYRE? MBX Biosciences received 3 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformMBX BiosciencesOutperform Votes4100.00% Underperform VotesNo VotesGyre TherapeuticsOutperform Votes1100.00% Underperform VotesNo Votes Does the media favor MBX or GYRE? In the previous week, Gyre Therapeutics had 13 more articles in the media than MBX Biosciences. MarketBeat recorded 13 mentions for Gyre Therapeutics and 0 mentions for MBX Biosciences. Gyre Therapeutics' average media sentiment score of 0.23 beat MBX Biosciences' score of 0.00 indicating that Gyre Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment MBX Biosciences Neutral Gyre Therapeutics Neutral Do analysts prefer MBX or GYRE? MBX Biosciences currently has a consensus target price of $37.25, suggesting a potential upside of 378.18%. Given MBX Biosciences' higher probable upside, equities research analysts clearly believe MBX Biosciences is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is MBX or GYRE more profitable? MBX Biosciences has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -84.57%. MBX Biosciences' return on equity of 0.00% beat Gyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MBX BiosciencesN/A N/A N/A Gyre Therapeutics -84.57%-118.43%-71.97% SummaryMBX Biosciences beats Gyre Therapeutics on 6 of the 11 factors compared between the two stocks. Remove Ads Get MBX Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBX vs. The Competition Export to ExcelMetricMBX BiosciencesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$260.37M$6.99B$5.68B$19.75BDividend YieldN/A2.72%4.55%3.75%P/E RatioN/A7.2324.5534.05Price / SalesN/A230.77395.7228.57Price / CashN/A65.6738.1617.54Price / BookN/A6.617.064.63Net IncomeN/A$142.13M$3.19B$1.02B7 Day Performance-7.48%2.79%1.49%1.12%1 Month Performance-20.27%2.70%5.87%-1.07%1 Year PerformanceN/A-4.42%14.94%7.08% MBX Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBXMBX Biosciences1.5202 of 5 stars$7.79-4.2%$37.25+378.2%N/A$260.37MN/A0.0036GYREGyre Therapeutics0.1133 of 5 stars$12.28+1.4%N/A-47.6%$1.15B$105.03M0.0040SNDXSyndax Pharmaceuticals3.7085 of 5 stars$13.04+0.7%$36.00+176.1%-39.2%$1.12B$23.68M-3.59110AUPHAurinia Pharmaceuticals2.5004 of 5 stars$8.40+2.9%$11.50+36.9%+71.6%$1.12B$235.13M-56.00300Positive NewsADPTAdaptive Biotechnologies3.4666 of 5 stars$7.54+3.6%$9.10+20.7%+167.3%$1.12B$178.96M-6.92790SYRESpyre Therapeutics1.8815 of 5 stars$18.54+2.8%$54.83+195.8%-53.8%$1.12B$890,000.00-2.48100Positive NewsSPRYARS Pharmaceuticals3.3548 of 5 stars$11.44-3.6%$31.00+171.0%+49.0%$1.11B$2.57M-22.4390Earnings ReportAnalyst RevisionNRIXNurix Therapeutics2.0567 of 5 stars$13.93+2.5%$30.88+121.7%-0.6%$1.06B$54.55M-4.82300ELVNEnliven Therapeutics2.877 of 5 stars$21.04+1.4%$38.25+81.8%+21.5%$1.03BN/A-11.0750NTLAIntellia Therapeutics4.4752 of 5 stars$9.58+4.8%$37.56+292.0%-65.4%$991.69M$57.88M-1.76600Analyst RevisionBGMQilian International Holding GroupN/A$10.03+4.5%N/AN/A$975.14M$25.10M0.00298Positive NewsGap Up Remove Ads Related Companies and Tools Related Companies Gyre Therapeutics Competitors Syndax Pharmaceuticals Competitors Aurinia Pharmaceuticals Competitors Adaptive Biotechnologies Competitors Spyre Therapeutics Competitors ARS Pharmaceuticals Competitors Nurix Therapeutics Competitors Enliven Therapeutics Competitors Intellia Therapeutics Competitors Qilian International Holding Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MBX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
